THIOLA (tiopronin) by Mission Therapeutics is cystine disulfide reduction [moa]. First approved in 1988.
Drug data last refreshed 8h ago · AI intelligence enriched Yesterday
THIOLA (tiopronin) is an oral small-molecule reducing agent approved in 1988 for cystinuria, a rare genetic disorder characterized by excessive urinary cystine excretion. It works by reducing cystine disulfide bonds to more soluble cysteine monomers, preventing kidney stone formation. The drug addresses a narrow, chronic patient population with limited treatment alternatives.
Declining market phase with modest Medicare utilization (512 claims, $3M annual spend) signals a shrinking commercial footprint and small marketing team.
Cystine Disulfide Reduction
Reducing and Complexing Thiol
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
THIOLA roles are limited and declining; zero linked job openings reflect the small, stable patient population and approaching loss of exclusivity. Career opportunities are primarily in maintaining physician relationships and reimbursement support rather than growth-driven expansion.
Worked on THIOLA at Mission Therapeutics? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/mo